Michele
Schoonmaker
Subject Matter Expert
About Michele
Early in her industry career, Michele served as Director of Medical Reimbursement at Vysis (now Abbott Molecular), where she helped pioneer dedicated reimbursement strategy for genetic and molecular cytogenetic tests at a time when most diagnostic companies had no such function. She then joined FDA’s Center for Devices and Radiological Health as a biologist reviewing diagnostic applications and supporting immunology advisory panels and guidance development. From there, she moved to the Congressional Research Service as a Specialist in Genetics, providing bipartisan, bicameral analysis to Congress on topics such as the regulation of medical devices, pharmacogenomics, personalized medicine, and Alzheimer’s policy—experience that sharpened her ability to translate complex science into objective, actionable policy options.
In 2005, Michele joined Cepheid and spent 17 years building and leading its Government Affairs function as the company grew from a $25M life sciences player into a multi-billion-dollar global diagnostics leader. As SVP of Government Affairs, she led a transatlantic team across four tightly connected pillars: health economics and reimbursement, government affairs and policy, professional relations, and external advocacy. While Cepheid was best known for its infectious disease portfolio, Michele also supported the company’s expanding oncology offerings—work that further deepened her insight into how high-complexity diagnostics are regulated, paid for, and integrated into clinical practice. She is particularly skilled at coalition-building—aligning medical societies, laboratory associations, patient groups, and policymakers around practical solutions that expand appropriate access to high-value testing.
Today, as owner of Michele Schoonmaker LLC and a Zensights Subject Matter Expert, Michele focuses on helping diagnostic and biopharmaceutical companies design evidence-driven market access strategies for novel and often first-in-class tests. She works with startups and established organizations alike to assess the market landscape, define regulatory and reimbursement pathways, and build integrated roadmaps for companion diagnostics, next-generation sequencing panels, and other precision medicine tools across oncology, cardiovascular disease, neurology, mental health, and rare disease. Companies turn to Michele when they need a 360-degree view—from FDA to CMS to Capitol Hill—of what it will take to secure coverage, payment, and real-world uptake for state-of-the-art diagnostic technologies. We couldn’t be more excited to bring Michele and her exceptional expertise onto the team.

